264 related articles for article (PubMed ID: 23154560)
1. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
[TBL] [Abstract][Full Text] [Related]
2. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K
Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175
[TBL] [Abstract][Full Text] [Related]
3. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
5. RET fusion genes in Korean non-small cell lung cancer.
Yoo SS; Jin G; Jung HJ; Hong MJ; Choi JE; Jeon HS; Lee SY; Lim JO; Park JY
J Korean Med Sci; 2013 Oct; 28(10):1555-8. PubMed ID: 24133367
[TBL] [Abstract][Full Text] [Related]
6. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract][Full Text] [Related]
7. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
8. The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.
Lin C; Wang S; Xie W; Chang J; Gan Y
Cancer Biol Ther; 2015; 16(7):1019-28. PubMed ID: 25975578
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.
Song Z; Yu X; Zhang Y
Lung Cancer; 2016 Nov; 101():16-21. PubMed ID: 27794403
[TBL] [Abstract][Full Text] [Related]
10. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
Wijesinghe P; Bepler G; Bollig-Fischer A
J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
[TBL] [Abstract][Full Text] [Related]
11. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Lee MS; Kim RN; I H; Oh DY; Song JY; Noh KW; Kim YJ; Yang JW; Lira ME; Lee CH; Lee MK; Kim YD; Mao M; Han J; Kim J; Choi YL
Oncotarget; 2016 Jun; 7(24):36101-36114. PubMed ID: 27150058
[TBL] [Abstract][Full Text] [Related]
13. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
[TBL] [Abstract][Full Text] [Related]
14. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
[TBL] [Abstract][Full Text] [Related]
15. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H
J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706
[TBL] [Abstract][Full Text] [Related]
16. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
[TBL] [Abstract][Full Text] [Related]
17. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
[TBL] [Abstract][Full Text] [Related]
18. Novel Human-Derived
Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
Hirai S; Idogawa M; Sumi T; Yamaguchi M; Niki T; Sakuma Y
Biochem Biophys Res Commun; 2022 Nov; 630():24-29. PubMed ID: 36126466
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Lee SH; Lee JK; Ahn MJ; Kim DW; Sun JM; Keam B; Kim TM; Heo DS; Ahn JS; Choi YL; Min HS; Jeon YK; Park K
Ann Oncol; 2017 Feb; 28(2):292-297. PubMed ID: 27803005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]